Name: Biosimilars and Interchangeable Biologics: Strategic Elements (en Inglés)
Price: 627917.00 COP
Availability: InStock
Author: Niazi, Sarfaraz K.
ISBN: 9781138775503

portada Biosimilars and Interchangeable Biologics: Strategic Elements (en Inglés)

Biosimilars and Interchangeable Biologics: Strategic Elements (en Inglés)

Formato

Libro Físico

Autor

Sarfaraz K. Niazi

Editorial

CRC Press

Idioma

Inglés

N° páginas

646

Encuadernación

Tapa Blanda

ISBN13

9781138775503

N° edición

Categorías

Farmacología
Farmacia/prescripción/dispensación
Biotecnología

Biosimilars and Interchangeable Biologics: Strategic Elements (en Inglés)

Sarfaraz K. Niazi (Autor) · CRC Press · Tapa Blanda

Libro Nuevo Importado

Envío: 15 a 21 días háb.

$ 1.255.834$ 627.917

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 10 unidades

$ 627.917

¡Envío Gratis! Llega entre el 09 Jul y el 21 Jul a Bogota, Cundinamarca. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Biosimilars and Interchangeable Biologics: Strategic Elements (en Inglés)"

What's the Deal with Biosimilars?Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development. Part of a two-volume set that covers varying aspects of biosimilars, Biosimilars and Interchangeable Biologics: Strategic Elements explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets.Of specific interest to practitioners, researchers, and scientists in the biopharmaceutical industry, this volume examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book also presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle.